1O: Osimertinib (osi) + datopotamab deruxtecan (Dato-DXd) in patients (pts) with EGFR-mutated (EGFRm) advanced NSCLC (aNSCLC) whose disease progressed on first-line (1L) osi: ORCHARDX. Le, Sarah B. Goldberg, Isamu Okamoto et al.|Journal of Thoracic Oncology|2025Cited by 22
PL04.07 FURTHER: A Global, Randomized Study of Firmonertinib at Two Dose Levels in TKI-Naive, Advanced NSCLC with EGFR PACC MutationsX. Le, J. Wang, Yu Yang et al.|Journal of Thoracic Oncology|2024Cited by 14